Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2-Reference-Cited by-同舟云学术

Enasidenib drives human erythroid differentiation independently of isocitrate dehydrogenase 2

Published:2020-03-03 Issue:4 Volume:130 Page:1843-1849
ISSN:0021-9738
Container-title:Journal of Clinical Investigation
language:en
Short-container-title:

Author:

Dutta Ritika,Zhang Tian Yi,Köhnke Thomas^ORCID,Thomas Daniel,Linde Miles,Gars Eric,Stafford Melissa,Kaur Satinder,Nakauchi Yusuke,Yin Raymond,Azizi Armon^ORCID,Narla Anupama^ORCID,Majeti Ravindra

Funder

NIH Office of the Director

Ludwig Institute for Cancer Research

Leukemia and Lymphoma Society

Howard Hughes Medical Institute

Stanford School of Medicine

Publisher

American Society for Clinical Investigation

Subject

General Medicine

Link

https://www.jci.org/articles/view/133344/files/pdf

Reference31 articles.

1. [No authors listed]. SEER Cancer Stat Facts: Acute Myeloid Leukemia. National Cancer Institute. https://seer.cancer.gov/statfacts/html/amyl.html Accessed February 24, 2020

2. Survival and cure of acute myeloid leukaemia in England, 1971-2006: a population-based study

3. AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations

4. Optimizing Next-Generation AML Therapy: Activity of Mutant IDH2 Inhibitor AG-221 in Preclinical Models

5. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of novel selective phosphodiesterase‑1 inhibitors for the treatment of acute myelogenous leukemia;Bioorganic Chemistry;2024-03

2. Next-generation therapy for lower-risk MDS;Hematology;2023-12-08

3. Raising the bar for lower-risk myelodysplastic syndromes;Leukemia & Lymphoma;2023-04-08

4. Research progress on molecular biomarkers of acute myeloid leukemia;Frontiers in Oncology;2023-02-07

5. A multiparametric niche-like drug screening platform in acute myeloid leukemia;Blood Cancer Journal;2022-06-24